Cases & Deals

MedImmune licenses in IP on antibodies that target IL-5 receptor

Clients MedImmune, Inc.

Jones Day represented MedImmune in an exclusive license to BioWa's POTELLIGENT technology platform and related intellectual property directed to antibodies that target the interleukin-5 (IL-5) receptor, including the transfer of Phase I clinical trials for treatment of asthma and other inflammatory diseases.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.